Effects of canagliflozin on anaemia in patients with type 2 diabetes and chronic kidney disease: a post-hoc analysis from the CREDENCE trial

Megumi Oshima 1, Brendon L Neuen 2, Meg J Jardine 3, George Bakris 4, Robert Edwards 5, Adeera Levin 6, Kenneth W Mahaffey 7, Bruce Neal 8, Carol Pollock 9, Norman Rosenthal 5, Takashi Wada 10, David C Wheeler 11, Vlado Perkovic 12, Hiddo J L Heerspink 13

Main idea: These data suggest that canagliflozin reduces the risk of anaemia-associated outcomes, including the need for erythropoiesis-stimulating agents, among patients with type 2 diabetes and chronic kidney disease.

Abstract

Background: Sodium-glucose co-transporter 2 inhibitors might enhance erythropoiesis and increase red blood cell mass. We assessed the long-term effects of canagliflozin on anaemia-related outcomes.

Methods: In a post-hoc analysis of the Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation trial, we included patients with type 2 diabetes and chronic kidney disease. All analyses were done by intention to treat and the primary outcome was a composite outcome of investigator-reported anaemia.

Findings: In a post-hoc analysis of the Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation trial, we included patients with type 2 diabetes and chronic kidney disease. All analyses were done by intention to treat and the primary outcome was a composite outcome of investigator-reported anaemia.

Source NIH